All Drug Development articles – Page 3
-
NewsBeige fat identified as potential target for blood pressure drugs
New research shows beige fat around blood vessels helps regulate blood pressure, offering potential pathways for future therapies to reduce cardiovascular risk.
-
ArticleDisrupting the biologics market through innovations in macrocycle R&D
New macrocycle technologies are turning a once difficult drug class into a scalable engine for developing potent oral therapies.
-
NewsClaudin 18.2-targeted therapy advances GI cancer treatment
A novel imaging-guided radiopharmaceutical targeting claudin 18.2 has shown that it can precisely detect and effectively treat gastric and pancreatic tumours, completely eradicating cancer in some preclinical models.
-
ArticleRethinking drug discovery through transcription factor biology
Complex diseases rarely have single targets. By focusing on transcription factor activity and disease signatures, Scripta Therapeutics is taking a different approach to identifying the drivers of pathology.
-
Article2026: the year AI stops being optional in drug discovery
AI is moving from a supporting role into the core of drug discovery. By 2026, it is expected to shape how targets are chosen, how biology is analysed and how development decisions are made.
-
NewsNew fluorescent technology tracks drug responses in cells
Researchers have developed new innovative fluorescent labels that allow scientists to observe cellular processes with unprecedented clarity – offering a powerful tool for medicine, drug research and cell biology.
-
NewsFunctional retinal organoids improve drug testing for eye disease
Researchers have developed vascularised human retinal organoids featuring the first fully functional light-signal pathways in lab-grown human retina models, opening new possibilities for studying eye disease and testing therapies.
-
Newsinsitro expands AI drug discovery with CombinAbleAI acquisition
insitro has acquired Israeli AI therapeutics company CombinAbleAI and launched its TherML platform, creating an end-to-end, modality-agnostic system for designing small molecules, antibodies, oligonucleotides and other complex biologics.
-
NewsNew study revives long-doubted target for depression drugs
Researchers have shown that changing the molecular structure of NK1 receptor antagonists may restore antidepressant effects after decades of failed trials.
-
ArticleAI steps into drug safety: predicting liver injury earlier than ever before
Drug-induced liver injury remains one of drug development’s most costly pitfalls. Now, AI and transcriptomics may offer a way to spot risks long before they reach patients.
-
NewsRare sugars point to future therapies for alcohol dependence
Researchers have identified a biological pathway linking sugar and appetite for alcohol, suggesting that rare sugars could one day form the basis of new therapies and approaches for reducing alcohol consumption and treating dependence.
-
NewsMagnetic stimulation advances heart organoids for future therapies
Researchers have shown that applying magnetic forces to lab-grown human heart organoids enhances their maturation and vascular development, offering a more realistic model of early heart formation and the possibility of future cardiac therapies.
-
NewsOTULIN enzyme found to drive tau and brain ageing
Researchers have discovered that the enzyme OTULIN, known for regulating the immune system, also drives the formation of tau – a protein linked to Alzheimer’s and other neurodegenerative diseases.
-
ArticleWhy tau still lacks treatments and how funders are responding
Tau drives PSP, CBD and other neurodegenerative diseases, yet there are still no disease-modifying treatments. Here, Dr Glenn Harris from the Rainwater Charitable Foundation shares how a coordinated funding effort is supporting basic research to understand tau mechanisms, improve detection and progress therapeutic development.
-
ArticleQuality over quantity: drug discovery automation in 2026
Automation in 2026 is no longer judged by the volume of experiments, but by the reliability of the evidence they produce. As complex biology and tighter budgets collide, industry leaders are pivoting toward automated workflows to secure the data integrity required for confident, early-stage decision-making.
-
NewsNew Type 2 diabetes drugs may improve insulin sensitivity
Scientists have used advanced computer modelling and lab techniques to design potential new diabetes drugs that improve insulin sensitivity.
-
NewsNew study links prenatal DNA screening to better CMV treatment decisions
A new study suggests that a low-cost form of non-invasive prenatal screening could help clinicians identify pregnant women at highest risk of transmitting cytomegalovirus to their babies.
-
NewsNew AI genomics platform targets kidney and cardiorenal disease
Seattle-based biotech company, Variant Bio, have launched Inference, an AI-powered genomics platform designed to accelerate drug discovery and identify genetically supported targets.
-
ArticleFertility beyond IVF: therapeutic advances in reproductive biotech
Procedural advances in IVF are reaching their biological limits. Reproductive biotech is now moving upstream, developing first in class therapeutics that target meiosis, gamete quality and implantation biology as druggable mechanisms in early discovery.
-
NewsNew Lumos AI platform targets precision in mental health drugs
Headlamp Health has launched Lumos AI®, a new decision-support platform designed to bring greater precision to neuroscience drug development.